An open-level, multicentre, dose-escalation, phase I study with an expansion phase, to evaluate safety, pharmacokinetics and therapeutic activity of RO6895882, an immunocytokine, consisting of a variant of interleukin-2 (IL-2v) targeting carcinoembryonic

Cancer type: Solide tumores

Phase: I

Principal Investigator: Joensuu Heikki

Country: FI

Keywords: Solide tumores, Phase 1, Finland

Status: Inclusion completed

Link to